Loading...
01/11 03:36
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals a mixed picture: while there are some positives, such as a payment from AbbVie and reduced operating expenses, the financial performance is concerning. Revenue has significantly decreased, there's a high cash burn rate, and the net loss has increased. The absence of detailed guidance and potential regulatory and competitive risks further weigh negatively. The market reaction is likely to be negative as the financial outlook appears weak, with uncertainties around future revenue and milestone payments.
GAAP Revenue Q4 2024 $164,000 (decrease of 45% from $299,000 in Q4 2023) due to lower sales of rhCollagen products.
GAAP Revenue Full Year 2024 $515,000 (decrease of 95% from $11 million in 2023) primarily due to a $10 million milestone payment received in 2023 from the AbbVie agreement.
GAAP Cost of Revenues Q4 2024 $272,000 (decrease of 65% from $773,000 in Q4 2023) mainly due to a decrease in royalty expenses and lower sales.
GAAP Cost of Revenues Full Year 2024 $1.6 million (decrease of 20% from $2 million in 2023) due to lower royalty expenses and a decrease in bioink and rhCollagen sales.
GAAP Gross Loss Q4 2024 $108,000 (improvement from a gross loss of $474,000 in Q4 2023) due to lower cost of revenues.
GAAP Gross Loss Full Year 2024 $1.1 million (decrease from a gross profit of $9 million in 2023) primarily due to the absence of the $10 million milestone payment in 2023.
GAAP Operating Expenses Q4 2024 $3.9 million (decrease of 15% from $4.6 million in Q4 2023) mainly due to lower employee salaries and reduced R&D activities.
GAAP Operating Expenses Full Year 2024 $16.1 million (decrease of 2% from $16.5 million in 2023) primarily due to lower general and administrative expenses.
GAAP Net Loss Q4 2024 $3.9 million or $0.34 per share (improvement from a net loss of $4.7 million or $0.41 per share in Q4 2023) due to lower operating expenses.
GAAP Net Loss Full Year 2024 $16.6 million or $1.45 per share (increase from a net loss of $7 million or $0.62 per share in 2023) mainly due to the absence of the $10 million milestone payment.
Cash and Cash Equivalents $11.9 million as of December 31, 2024, with a cash runway expected to last through the second quarter of 2026.
Cash Used in Operating Activities Full Year 2024 $14.1 million (increase from $2.8 million in 2023) due to increased operational expenditures.
Cash Used in Investing Activities Full Year 2024 $539,000 (decrease from $1.2 million provided in 2023) primarily related to property and equipment purchases.
Cash Provided by Financing Activities Full Year 2024 $9,000 (decrease from $1.1 million in 2023) due to the absence of proceeds from warrant exercises.
Photocurable Dermal Filler: CollPlant is advancing its photocurable dermal filler candidate, currently in preclinical phase, targeting a market valued at approximately $6.3 billion with a 10% CAGR. Positive feedback from thought leaders suggests it could revolutionize facial plastic surgery.
Regenerative Breast Implants: CollPlant is advancing preclinical testing of its regenerative breast implants, now at a commercial size of 200cc. Early results show promising outcomes in tissue integration and vascularization, with no complications observed.
Collaboration with AbbVie: CollPlant's collaboration with AbbVie is focused on developing dermal and soft tissue filler products, with interim results from clinical trials being reviewed. A $2 million payment was received from AbbVie following a development achievement.
Cost Reduction: GAAP operating expenses decreased to $3.9 million in Q4 2024 from $4.6 million in Q4 2023, primarily due to reduced employee salaries and R&D activities.
Cash Position: As of December 31, 2024, CollPlant had $11.9 million in cash, expected to support operations through Q2 2026, following a $2 million payment from AbbVie in Q1 2025.
Revenue Decrease: GAAP revenues for Q4 2024 were $164,000, down from $299,000 in Q4 2023, primarily due to reduced sales of rhCollagen products.
Annual Revenue Decline: GAAP revenue for the year ended December 31, 2024, was $515,000, significantly lower than $11 million in 2023, largely due to a $10 million milestone payment received in 2023.
Increased Net Loss: GAAP net loss for Q4 2024 was $3.9 million, compared to $4.7 million in Q4 2023, and for the year, it was $16.6 million, up from $7 million in 2023.
Cash Burn Rate: Cash used in operating activities during 2024 was $14.1 million, a significant increase from $2.8 million in 2023, indicating a higher cash burn rate.
Regulatory Risks: The company is engaged in the development of products that require regulatory approval, which poses risks related to compliance and potential delays.
Market Competition: The aesthetic medicine market is highly competitive, with numerous players, which may impact CollPlant's market share and pricing strategies.
Supply Chain Challenges: The company may face supply chain challenges that could affect the production and delivery of its products, particularly in the context of ongoing global supply chain disruptions.
Economic Factors: Economic downturns or changes in healthcare spending could adversely affect demand for CollPlant's products and services.
Photocurable Dermal Filler Candidate: In preclinical phase, targeting a market valued at approximately $6.3 billion with a 10% CAGR. Positive feedback from thought leaders suggests it could be a game changer in aesthetic medicine.
Collaboration with AbbVie: Focus on developing dermal and soft tissue filler products. AbbVie is currently reviewing interim results from clinical trials initiated in 2023, with next steps to be determined.
Regenerative Breast Implants: Advancing preclinical testing of commercial size breast implants (200cc). Promising outcomes observed in one study arm, with no complications and maintained mechanical properties.
Recombinant Human Collagen Technology: Continuous demand for bioinks and other applications. Engaged in discussions with various companies interested in accessing rhCollagen.
Cash Runway: Cash balance of $11.9 million as of December 31, 2024, expected to satisfy operational requirements through Q2 2026.
Future Revenue Expectations: GAAP revenues for 2024 were $515,000, a decrease from $11 million in 2023 due to a one-time $10 million payment from AbbVie in 2023.
Operating Expenses: GAAP operating expenses for 2024 were $16.1 million, a slight decrease from $16.5 million in 2023.
Net Loss: GAAP net loss for 2024 was $16.6 million, compared to $7 million in 2023, primarily due to the previous year's milestone payment.
AbbVie Payment: CollPlant received a $2 million payment from AbbVie during Q1 2025 following a development achievement under the AbbVie agreement.
2023 Milestone Payment: In 2023, CollPlant achieved a milestone with respect to the AbbVie agreement, which triggered a $10 million payment.
The company's financial performance shows a significant decline in revenue and increased cash burn, despite a reduced net loss. The Q&A section highlights uncertainties with AbbVie milestones and unclear management responses, adding to investor concerns. Additionally, the cash runway suggests potential liquidity issues. These factors, combined with competitive pressures and regulatory risks, likely lead to a negative stock price reaction.
Despite some positive developments, such as the collaboration with AbbVie and cash management strategies, the overall financial performance is weak, with declining revenues and increased net losses. The lack of clear guidance from management, combined with regulatory risks and competitive market pressures, further contribute to a negative sentiment. The Q&A session highlighted uncertainties about future milestone payments and revenue streams, adding to investor concerns. These factors suggest a negative stock price reaction in the near term.
The earnings call reveals a mixed picture: while there are some positives, such as a payment from AbbVie and reduced operating expenses, the financial performance is concerning. Revenue has significantly decreased, there's a high cash burn rate, and the net loss has increased. The absence of detailed guidance and potential regulatory and competitive risks further weigh negatively. The market reaction is likely to be negative as the financial outlook appears weak, with uncertainties around future revenue and milestone payments.
The financial performance shows a significant revenue decline and increased net losses, primarily due to the absence of milestone payments. Despite positive preclinical study results and ongoing partnerships, the lack of immediate new agreements and the focus on securing non-dilutive cash suggest operational and funding challenges. The Q&A section reveals uncertainty about future agreements, which could unsettle investors. The company's operational efficiency improvements are overshadowed by financial struggles, leading to a negative sentiment likely affecting the stock price in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
